MANGOCEUTICALS, INC.
For the period ended Mar 31, 2025. Filed May 15, 2025.
View on SEC.govAbout this filing
A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.
Mar 31, 2025 · Filed May 15, 2025
MGRX$0.19-4.0%Stored close · as of Nov 10, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Condensed Consolidated Statements of Cash Flows
| For the Three · For the | ||||
|---|---|---|---|---|
| Months Ended · Year Ended | ||||
| March 31, 2025 · March 31, 2024 | ||||
| CASH FLOWS FROM OPERATING ACTIVITIES: | ||||
| Net loss | $(4,839,489) | $(2,367,617) | ||
| Adjustments to reconcile net loss to net cash used in operating activities: | ||||
| Depreciation | 250 | 6,224 | ||
| Issuance of common stock for services | 1,938,500 | 416,500 | ||
| Imputed interest expense | - | - | ||
| Options vested for stock-based compensation | 50,979 | 37,965 | ||
| Loss on sale of assets | - | - | ||
| Operating lease right of use asset | 15,719 | 14,470 | ||
| Amortization of license agreement | 137,927 | - | ||
| Amortization on intangible assets | 276,815 | - | ||
| Inventory | - | - | ||
| (Increase) decrease in operating assets: | ||||
| Inventory | - | 4,049 | ||
| Prepaid expenses | (83,214) | 902 | ||
| Prepaid expenses - related party | - | - | ||
| (Decrease) increase in operating liabilities: | ||||
| Accounts payable and accrued liabilities | 340,678 | 875,180 | ||
| Accounts payable and accrued liabilities - related parties | - | 35,000 | ||
| Operating lease right of use liabilities | (17,249) | (15,412) | ||
| Payroll tax liabilities | - | 1,608 | ||
| Other liabilities | (121,576) | - | ||
| Other liabilities - related party | 25,879 | - | ||
| NET CASH USED IN OPERATING ACTIVITIES | (2,274,781) | (991,131) | ||
| CASH FLOWS FROM FINANCING ACTIVITIES: | ||||
| Proceeds from borrowings on notes payable - related parties | - | 87,500 | ||
| Proceeds from sales of common stock for cash | 655,000 | 180,000 | ||
| Proceeds from sales of preferred stock for cash | 1,150,000 | - | ||
| Proceeds from exercise of warrants | 480,000 | - | ||
| NET CASH PROVIDED BY FINANCING ACTIVITIES | 2,285,000 | 267,500 | ||
| NET INCREASE (DECREASE) IN CASH AND CASH EQUIVALENTS | ||||
| End of period | 10,220 | (723,631) | ||
| CASH AND CASH EQUIVALENTS: | ||||
| Beginning of period | 58,653 | 739,006 | ||
| Effects of currency translation on cash and cash equivalents | 7,624 | (70) | ||
| End of period | $76,496 | $15,305 | ||
| Supplemental disclosure of cash flow information: | ||||
| Cash paid for income taxes | $ | - | $ | - |
| Cash paid for interest | $ | - | $ | - |
| $ | - | $ | - | |
| Supplemental schedule of non-cash investing and financing activities: | ||||
| Issuance of common stock for master distribution agreement | $6,713,000 | $ | - | |
| Series C Convertible Preferred accrued dividend | $294,000 | $ | - | |
| Issuance of common stock for settlement of note payable | $150,000 | |||
| Issuance of common stock for conversion of Series B Convertible Preferred | $1,581,812 | $ | - | |
Mangoceuticals, Inc.
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.